Home › Diffuse Large B-Cell Lymphoma › Colorado
Diffuse Large B-Cell Lymphoma clinical trials in Colorado
19 studies for Diffuse Large B-Cell Lymphoma are looking for participants at sites in Colorado.
Cities in Colorado
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
- Rocky Mountain Cancer Centers, Lone Tree
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT06500273Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
- Children's Hospital Colorado, Aurora
RecruitingObservational study
Ages 0 to 38 · All sexes · Updated Oct 1, 2026 · NCT06131801A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
- Uchealth North, Fort Collins
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT05006716A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
- Lutheran Hospital - Cancer Centers of Colorado ( Site 0180), Golden
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06717347A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)
- Colorado Blood Cancer Institute ( Site 7000), Denver
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT07519772A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
- Rocky Mountain Cancer Centers (RMCC) ( Site 8001), Aurora
- Colorado West Healthcare System-Grand Valley Oncology ( Site 0165), Grand Junction
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06890884A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
- Colorado Blood Cancer Institute, Denver
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07226843A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
- University of Colorado Denver - School of Medicine - Anschutz Medical Campus, Aurora
- Colorado Blood Cancer Institute, Denver
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07101328Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
- Children's Hospital Colorado-Center for Cancer and Blood Disorders ( Site 1016), Aurora
RecruitingPhase 1/2
6 Months – 25 Years · All sexes · Updated Sep 17, 2026 · NCT06395103Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
- Rocky Mountain Cancer Centers, LLP, Aurora
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 11, 2026 · NCT06806033Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
- Colorado Blood Cancer Institute, Denver
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 25, 2026 · NCT05826535Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- Colorado Blood Cancer Institute, Denver
RecruitingPhase 1/2
Ages 13 to 90 · All sexes · Updated Aug 6, 2026 · NCT06533579A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
- University of Colorado, Aurora
- Colorado Blood Cancer Institute, Denver
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 4, 2026 · NCT07188558DALY II USA/ MB-CART2019.1 for DLBCL
- Colorado Blood Cancer Institute, Denver
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jul 13, 2026 · NCT04792489A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
- Colorado Blood Cancer Institute, Denver
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 2, 2026 · NCT05131022SynKIR-310 for Relapsed/Refractory B-NHL
- Colorado Blood Cancer Institute, part of Sarah Cannon Cancer Institute, Denver
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Apr 14, 2026 · NCT06544265A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
- Sarah Cannon Research Institute at Colorado Blood Cancer Institute, Denver
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Mar 20, 2026 · NCT04830137A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
- Colorado Blood Cancer Institute, Denver
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 2, 2025 · NCT05780034A Study of NX-1607 in Adults With Advanced Malignancies
- University of Colorado School of Medicine, Aurora
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 9, 2025 · NCT05107674From ClinicalTrials.gov, data retrieved Oct 3, 2026. Each study sets its own eligibility; the study team decides who can join.